NASDAQ:INSM Insmed Q3 2026 Earnings Report $108.59 -5.55 (-4.86%) Closing price 10/1/2026 04:00 PM EasternExtended Trading$109.08 +0.48 (+0.45%) As of 04:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Insmed EPS ResultsActual EPSN/AConsensus EPS -$0.39Beat/MissN/AOne Year Ago EPSN/AInsmed Revenue ResultsActual RevenueN/AExpected Revenue$500.95 millionBeat/MissN/AYoY Revenue GrowthN/AInsmed Announcement DetailsQuarterQ3 2026Date10/29/2026TimeBefore Market OpensConference Call DateThursday, October 29, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Insmed Earnings HeadlinesContrasting Agios Pharmaceuticals (NASDAQ:AGIO) & Insmed (NASDAQ:INSM)September 29 at 4:45 AM | americanbankingnews.comInsmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?September 28, 2026 | insidermonkey.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation. | Paradigm Press (Ad)Insmed (NASDAQ:INSM) Stock Rated "Buy" in New Coverage at The Goldman Sachs GroupSeptember 27, 2026 | americanbankingnews.comMizuho Securities Sticks to Its Buy Rating for Insmed (INSM)September 25, 2026 | theglobeandmail.comInsmed, Inc. (NASDAQ:INSM) Receives Average Recommendation of "Buy" from BrokeragesSeptember 25, 2026 | americanbankingnews.comSee More Insmed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Insmed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Insmed and other key companies, straight to your email. Email Address About InsmedInsmed (NASDAQ:INSM) Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options. Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients. The product is marketed in the United States and has also received regulatory authorization in other major markets, including Europe and Japan. The company is also advancing a pipeline of investigational therapies, including brensocatib, an oral anti-inflammatory treatment being developed for bronchiectasis, and treprostinil palmitil inhalation powder, an inhaled therapy being studied for pulmonary arterial hypertension and other pulmonary conditions. Insmed is headquartered in Bridgewater, New Jersey, and is led by President and Chief Executive Officer Will Lewis.View Insmed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
